Penn
Penn Pharma has announced its latest plans to invest in additional specific tablet manufacturing and coating capacity to meet customer demand. This investment is in addition to the £14 million recently invested in a solid dose contained manufacturing facility to handle potent APIs.
Penn Pharma Chief Executive Officer Richard Yarwood commented: “We are making this additional significant investment to meet our growing customer demands. It is fuelled by our demonstrated ability to provide pragmatic and timely solutions for their needs. At a time when many businesses are struggling, we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers.”
The new £3 million investment follows the recent completion of Penn Pharma’s new 1,394 m2 site for the clinical and commercial manufacture of tablets and capsules. The facility will deliver both the clinical and commercial contained manufacturing needs of its clients.
Penn Pharma Chief Operating Officer Mark Dean-Netscher also commented: “Again, we at Penn are demonstrating our commitment to our customers and our growth as a business. This additional investment will ensure we deliver to our customers and exceed expectations.”
Penn Pharma has been providing pharmaceutical services for over 30 years and employs 275 staff on its two sites in South Wales, UK. It has twice won the prestigious Queen’s Award for Enterprise in recognition of the work it provides to export markets including the US and Japan.
Penn Pharmaceutical Services Ltd, +44 1495 711 222, www.pennpharm.co.uk.